<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04233801</url>
  </required_header>
  <id_info>
    <org_study_id>1245-0191</org_study_id>
    <nct_id>NCT04233801</nct_id>
  </id_info>
  <brief_title>A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Empagliflozin (10 mg and 25 mg) Administered Orally Once Daily in Combination With Insulin With or Without up to Two Oral Anti-diabetic Agents for 24 Weeks in Chinese Type 2 Diabetic Patients With Insufficient Glycemic Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the current study is to investigate the efficacy and safety of Empagliflozin
      compared to placebo given for 24 weeks in combination with stable insulin with or without up
      to two oral antidiabetic drugs in Chinese patients with T2DM with insufficient glycemic
      control.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2020</start_date>
  <completion_date type="Anticipated">February 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 7, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in glycosylated haemoglobin A1c (HbA1c)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c&lt;7.0%</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure (SBP)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure (DBP)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (FPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Post-prandial Glucose (PPG)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of hypoglycemic events</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adjudicated diabetic ketoacidosis (DKA) events</measure>
    <time_frame>28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">273</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Empagliflozin</description>
    <arm_group_label>Empagliflozin high dose</arm_group_label>
    <arm_group_label>Empagliflozin low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years and ≤75 years old at Visit 1;

          -  Chinese patient with diagnosis of Type 2 diabetes prior to Visit 1;

          -  A stable treatment with premixed Insulin (≥ 20IU/day) or basal insulin (≥ 16 IU/day)
             for at least 12 weeks prior to enrolment with or without up to two OADs

               -  With maximum insulin dose of ≤ 1 unit/kg/day. Acceptable basal insulins with
                  duration of action up to 24 h could be insulin glargin, insulin detemir or NPH
                  (neutral protamine hagedorn) insulin; Acceptable pre-mixed insulins could be once
                  or twice daily posology only. The total insulin dose should not be changed by
                  more than 20% of the baseline value within the 12 weeks prior to randomisation
                  (Visit 3). Both human insulin &amp; insulin analogue are acceptable;

               -  If the patient is taking OADs, regimen has to be unchanged for at least 12 weeks
                  prior to randomization (Visit 3);

               -  If the patient is taking metformin, stable dose (at least 1500 mg daily or
                  maximum tolerated dose) must be maintained for at least 12 weeks without dose
                  adjustments prior to randomization (Visit 3);

          -  HbA1c ≥7.5% and ≤11.0% at Visit 1;

          -  Fasting C-peptide: &gt;0.5 ng/mL at Visit 1；

          -  18.5 kg/m2 ≤ BMI ≤ 45 kg/m2 at Visit 1;

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial;

          -  Male or female patients. Women of childbearing potential (WOCBP) must be ready and
             able to use highly effective methods of birth control per ICH M3 (R2) that result in a
             low failure rate of less than 1% per year when used consistently and correctly. A list
             of contraception methods meeting these criteria is provided in the patient
             information.

        Exclusion Criteria:

          -  Diagnosis of Type 1 diabetes;

          -  Patients receiving MDI insulin or insulin pump treatment;

          -  eGFR &lt;45ml/min/1.73m2 calculated based on MDRD formula;

          -  Uncontrolled hyperglycemia [glucose level &gt;13. 9 mmol/l after an overnight fast during
             placebo run-in];

          -  Severe hypoglycemia episode (event requiring the assistance of another person to
             actively administer carbohydrate, glucagon or other resuscitative actions) within 6
             months prior to Visit 1;

          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma. Myocardial
             infarction, stroke or transient ischaemic attack within 3 months prior to Visit 1;

          -  Bariatric surgery;

          -  Further criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqing Zhang</last_name>
      <phone>13611167278</phone>
      <email>junqing.zhang@pkufh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>101200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yufeng Li</last_name>
      <phone>010-89992258</phone>
      <email>pgyylyf@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanqing Cai</last_name>
      <phone>13674315020</phone>
      <email>caihanqing16@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <zip>404000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Luo</last_name>
      <phone>13594761986</phone>
      <email>yuyuanlyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Hangzhou</city>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yibing Lu</last_name>
      <phone>18951762690</phone>
      <email>luyibing2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <zip>310015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiuling Zhang</last_name>
      <phone>86-18989873772</phone>
      <email>nfmkzql@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <zip>471000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liujun Fu</last_name>
      <phone>13461027196</phone>
      <email>flj923@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingdong Liu</last_name>
      <phone>86 13970921669</phone>
      <email>easd04ljd@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianying Liu</last_name>
      <phone>13970053600</phone>
      <email>13970053600@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongren hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shan Huang</last_name>
      <phone>13917219119</phone>
      <email>13917219119@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Fifth People's Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Liu</last_name>
      <phone>18918168586</phone>
      <email>17091325695@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suzhou Municipal Hospital</name>
      <address>
        <city>Suzhou</city>
        <zip>215002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Chen</last_name>
      <phone>15906131360</phone>
      <email>szlei2004@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bimin Shi</last_name>
      <phone>0512-67780319</phone>
      <email>shibimin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim. com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>http://trials.boehringer-ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

